Incubation of our cells with the c-MYC inhibitor as expected led to a decreased number of viable cells (Fig. 4a) with IC50 values (6.48–10.23 μM) in the lower range seen in other cell systems (breast cancer cells: 20–30 μM [50]; multiple myeloma cell lines: 12–45 μM [51]; ovarian carcinoma cell lines: 3.2 and 4.4 μM [52]; HepG2 hepatocellular carcinoma cells: around 100 μM [53]; acute myeloid leukemia (AML) cell lines: 60–90 μM [54]). This evidence concerns the gene MYC and plasma cell myeloma.